#Germany #Berlin #radiopharmaceuticals #Pentixapharm #PANDA Study

Pentixapharm Advances its Pivotal Phase 3 PANDA Study

Pentixapharm Holding AG, a prominent clinical-stage biotechnology firm focusing on revolutionary radiopharmaceutical diagnostics and therapies, has announced promising developments concerning its pivotal Phase 3 PANDA study. As part of their commitment to innovation in healthcare, the company has made significant strides in preparing for the upcoming study, designed specifically to address primary aldosteronism.

On November 12, 2026, Pentixapharm will host a webcast at 3 p.m. CET (200 p.m. GMT / 900 a.m. EST), where management will present their financial results for the third quarter and first nine months of 2026, alongside key updates about the PANDA study. The study, which seeks to enroll about 325 participants, has already begun the patient enrollment process at selected leading academic medical centers across the United States. The initial patient enrollment is anticipated to commence in the first quarter of 2027.

One pivotal aspect of the PANDA study is its commitment to safety and ethical standards. The central ethics committee in the U.S. has approved the study protocol, which defines the primary endpoints and indicates that approximately 325 patients will be involved. This approval reflects the extensive preparations that Pentixapharm has undertaken to ensure compliance with regulatory requirements.

The PANDA study leverages the investigational radiopharmaceutical candidate, [68Ga]Ga-PentixaFor, for non-invasive subtyping in adults diagnosed with primary aldosteronism. This condition, often undetected, is a significant hormonal contributor to hypertension. The study aims to identify candidates who may benefit from surgical intervention, which currently requires invasive procedures for accurate diagnosis. By utilizing [68Ga]Ga-PentixaFor, Pentixapharm aims to revolutionize the diagnostic process, making it less invasive and more accessible for patients.

Pentixapharm has received the Fast Track designation from the FDA for the PANDA study, granting the company a streamlined approach to development and review processes. This designation underscores the anticipated impact that the study could have on patient care and treatment options for those suffering from primary aldosteronism. The FDA has also confirmed that there are no concerns regarding the submitted study protocol, further validating the company's approach and methodologies.

With more than ten U.S. study locations already designated, Pentixapharm is actively negotiating agreements with these sites to facilitate a smooth and efficient enrollment process. In their recent communications, Pentixapharm reiterated their confidence in the study's timeline, assuring stakeholders that no significant delays are expected.

As the webcast approaches, Pentixapharm invites interested parties to register for the event, where company leaders will discuss not only the PANDA study progress but also offer insights into the broader development portfolio. Following the live event, a recording will be made available on the company's official website, catering to investors and stakeholders who wish to stay updated on their endeavors.

About Pentixapharm

Pentixapharm Holding AG, located in Berlin, is at the forefront of the clinical-stage biotechnology arena, dedicated to developing innovative nuclear medicine strategies. The company focuses on creating effective radiopharmaceuticals tailored to enhance the precision of diagnosing and treating severe health conditions. Their ongoing projects include a varied pipeline targeting several medical areas, namely endocrine, cardiovascular, and oncology.

With an unwavering dedication to groundbreaking medical advancements, Pentixapharm continues to forge pathways toward improved diagnostic solutions in the healthcare landscape. The PANDA study promises to be a pivotal effort in this journey, potentially altering the course of treatment for many individuals suffering from poorly diagnosed conditions.